Europe's rearmament has moved from political rhetoric to signed contracts, and the shift is visible on the London market. Higher NATO spending commitments, the restocking of munitions after years of donations to Ukraine, and a UK pledge to lift defence outlays as a share of GDP have handed British suppliers some of their fullest order books in a generation. Three FTSE 250 names sit close to the centre of that story. QinetiQ is a research-led testing and services group; Chemring Group makes countermeasures and energetic materials; and Avon Technologies supplies respiratory and ballistic protection to armed forces and first responders. All three reported during 2026, and each shows how rising budgets feed through - unevenly - into revenue, profit and cash.
QinetiQ (LSE:QQ.)
QinetiQ delivered its full-year results for the 12 months to 31 March 2026 on 21 May, and the shares rose around 8% on the day. Revenue was broadly flat at £1,923m (FY25: £1,932m), but underlying operating profit climbed 18% to £218m as the Margin widened to 11.3%. Organic revenue growth of 1.3% was led by a strong UK performance. The headline figure was order intake: a record £3,573m, up 83%, boosted by a £1,543m extension to the Long Term Partnering Agreement, which lifted year-end Backlog to £4.8bn. Free Cash Flow rose 41% to £159m, net Debt stood at £159m (0.5x EBITDA), and the full-year Dividend was raised 24% to 11.00p. The board also extended its buyback to £100m a year through FY29. Underlying Earnings Per Share came in at 31.5p, ahead of market expectations, and management pointed to medium-term guidance of 3-5% organic revenue growth and operating margins of 11-11.5%. The most closely watched item, though, was strategic rather than financial: QinetiQ said it is "assessing the strategic fit" of its US business, with all Options under review, after US revenue fell to £393.4m from £453.9m following the disposal of its Federal IT portfolio. This is a review of QinetiQ's own American unit - not a Takeover approach for the group - and any divestment would reshape the portfolio and, potentially, lift group margins.
Chemring Group (LSE:CHG)
Chemring's half-year figures, published on 2 June 2026 for the six months to 30 April, told a more mixed story. Revenue rose 7% to £237.3m, yet underlying operating profit slipped 8% to £24.5m and statutory operating profit fell 25% to £21.7m, as Investment and cost pressures weighed on margins. Underlying diluted earnings came in at 6.1p, and the Interim Dividend edged up 4% to 2.8p. The standout was the order book, which reached a record £1,399.4m, with the group noting that around 91% of expected 2026 revenue was already delivered or contracted. Net debt was £144.5m, or 1.47x underlying EBITDA, reflecting heavy Capital spending - some £44m in the half - on energetics capacity in the United States, Scotland and Norway, where Chemring Nobel is being expanded. The Countermeasures & Energetics arm generated the bulk of profit, at £26.1m, against £9.6m for Sensors & Information. During the period Chemring also secured contract awards including work on the US JBTDS biological-threat detection programme and further Alloy Surfaces countermeasure orders, both of which feed that record backlog. It announced a group chief executive retirement and succession process in late July, adding a Leadership transition to an already investment-heavy phase.
Avon Technologies (LSE:AVON)
Avon Technologies - formerly Avon Protection, and before that Avon Rubber - is now a pure-play protection specialist based in Melksham, Wiltshire, with substantial US Department of Defense exposure. Its products span respiratory systems such as the FM50 mask and filters, and ballistic head protection including the ACH GEN II and Next Generation IHPS helmets, alongside the Team Wendy range. Interim results to 31 March 2026, released on 13 May, showed revenue up 6.8% in constant currency to $160.8m and adjusted operating profit up 39.4% to $24.4m, with adjusted pre-tax profit of $21.8m and adjusted earnings of 56.4 cents. The interim dividend rose to 8.1 cents. Reflecting the lumpy nature of defence procurement, orders received fell 31.6% to $117.9m and the closing order book eased 11.4% to $219.9m, while net debt was $58.0m. Management said it was on track to meet or exceed FY26 guidance and would set new medium-term targets with the full-year results. A run of contract awards followed the half, including ACH GEN II delivery orders worth $20.1m and $20.3m and further European NATO respirator business. Even so, the shares fell after the results as investors weighed the softer order intake against the strong profit growth - a reminder that, in defence, the timing of big contracts can matter as much as the headline earnings.
How the Three Companies Compare
The trio offer three different ways to play the same tailwind. QinetiQ sells knowledge - testing, evaluation and mission-led services - and its swing Factor is the fate of its US operations. Chemring sells consumables: countermeasures and energetic materials that are used up and reordered, giving it a record backlog but, for now, squeezed margins as it builds capacity. Avon sells wearable protection, a higher-margin niche whose order flow is inherently uneven and reported in US dollars. All three are riding structurally higher budgets, but they sit at different points in the cash-conversion cycle.
What to Watch Next
For QinetiQ, the outcome of the US strategic review is the near-term catalyst, alongside progress on the buyback and delivery against LTPA work. For Chemring, the questions are whether its incoming leadership can convert the record order book into rising profit and how quickly the energetics investment pays back. For Avon, investors will watch for a recovery in order intake, confirmation of FY26 guidance and the promised medium-term targets, plus the dollar's direction. Across the sector, budget timing, programme delays and shifting US priorities remain the main risks.
QinetiQ, Chemring and Avon show that "defence spending rises" is not one trade but several. Records in orders and backlog are real, yet they arrive with margin pressure, heavy capital needs and strategic decisions still to be made - a reminder that a strong sector backdrop does not guarantee a smooth path for every constituent.




_11_18_2026_14_55_02_703826.jpg)

Please wait processing your request...